David Socks - Hillevax Chief Officer
| HLVX Stock | USD 1.86 0.03 1.64% |
Executive
David Socks is Chief Officer of Hillevax
| Age | 49 |
| Address | 321 Harrison Avenue, Boston, MA, United States, 02118 |
| Phone | 617 213 5054 |
| Web | https://www.hillevax.com |
David Socks Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Socks against Hillevax stock is an integral part of due diligence when investing in Hillevax. David Socks insider activity provides valuable insight into whether Hillevax is net buyers or sellers over its current business cycle. Note, Hillevax insiders must abide by specific rules, including filing SEC forms every time they buy or sell Hillevax'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Socks over two months ago Discretionary transaction by David Socks of tradable shares of Hillevax subject to Rule 16b-3 | ||
David Socks over six months ago Disposition of 17500 shares by David Socks of Phathom Pharmaceuticals at 10.3 subject to Rule 16b-3 | ||
David Socks over a year ago Acquisition by David Socks of 9000 shares of Phathom Pharmaceuticals subject to Rule 16b-3 |
Hillevax Management Efficiency
The company has return on total asset (ROA) of (0.289) % which means that it has lost $0.289 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6224) %, meaning that it created substantial loss on money invested by shareholders. Hillevax's management efficiency ratios could be used to measure how well Hillevax manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.34 in 2025. Return On Capital Employed is likely to rise to -0.46 in 2025. At this time, Hillevax's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 322.7 M in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 1 M in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| David CFA | PepGen | N/A | |
| Magnus DPHIL | Monte Rosa Therapeutics | N/A | |
| Chad Cowan | Century Therapeutics | N/A | |
| Douglas CPA | Century Therapeutics | N/A | |
| Kenneth Sall | Opthea | N/A | |
| Maryellen McQuade | NewAmsterdam Pharma | N/A | |
| Mr MBA | C4 Therapeutics | 46 | |
| Rose Weldon | Cullinan Oncology LLC | N/A | |
| David MD | Mineralys Therapeutics, Common | 70 | |
| Sheng Cui | NewAmsterdam Pharma | N/A | |
| Binh Vu | Pmv Pharmaceuticals | N/A | |
| Douglas Kling | NewAmsterdam Pharma | 52 | |
| MD MBA | Molecular Partners AG | N/A | |
| Andrew Funderburk | Monte Rosa Therapeutics | N/A | |
| Venkatesh Srinivasan | Sutro Biopharma | 63 | |
| MA JD | Sutro Biopharma | N/A | |
| Thomas Reilly | Opthea | 53 | |
| Tim Smith | Pmv Pharmaceuticals | N/A | |
| Kerry MS | Entrada Therapeutics | N/A | |
| Marc MD | Pmv Pharmaceuticals | N/A | |
| Peter MBA | Opthea | 52 | |
Management Performance
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.29 |
Hillevax Leadership Team
Elected by the shareholders, the Hillevax's board of directors comprises two types of representatives: Hillevax inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hillevax. The board's role is to monitor Hillevax's management team and ensure that shareholders' interests are well served. Hillevax's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hillevax's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anju Chatterji, VP Operations | ||
| Kaia Agarwal, VP Affairs | ||
| Astrid MD, Chief Officer | ||
| Shane Maltbie, CFO Treasurer | ||
| Sean McLoughlin, Chief Officer | ||
| Paul JD, Secretary Counsel | ||
| Ozzie Berger, Senior Affairs | ||
| David Socks, Chief Officer | ||
| Aditya Kohli, CoFounder Director |
Hillevax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hillevax a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | (71.7 M) | ||||
| Shares Outstanding | 49.81 M | ||||
| Shares Owned By Insiders | 17.11 % | ||||
| Shares Owned By Institutions | 72.65 % | ||||
| Number Of Shares Shorted | 1.52 M | ||||
| Price To Book | 0.50 X | ||||
| EBITDA | (132.47 M) | ||||
| Net Income | (123.57 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Hillevax Stock Analysis
When running Hillevax's price analysis, check to measure Hillevax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hillevax is operating at the current time. Most of Hillevax's value examination focuses on studying past and present price action to predict the probability of Hillevax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hillevax's price. Additionally, you may evaluate how the addition of Hillevax to your portfolios can decrease your overall portfolio volatility.